The Global Pharmaceutical Contract Development Market in terms of revenue was estimated to be worth $176.5 billion in 2023 and is poised to reach $258.3 billion by 2028, growing at a CAGR of 7.9% from 2023 to 2028. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

Various elements such as rising research activities and funding investments for generic medicines, technological advancements in CDMOs, the high cost of in-house drug development, and the regulatory filling support provided by CDMOs, are driving the market growth.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=201524381

Browse in-depth TOC on “Pharmaceutical Contract Development Market”

244 – Tables

47 – Figures

289 – Pages

Key Market Players

The global pharmaceutical contract development and manufacturing market is highly consolidated. Key players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), AbbVie Inc. (US), Aenova Group (Germany), Almac Group (UK), Siegfried Holding AG (Switzerland). Acquisitions and product launches are the key growth strategies undertaken by these companies to maintain their positions in the market.

1. Market Size and Growth:

1. The global pharmaceutical contract development market was estimated to be worth $176.5 billion in 2023.
2. It is projected to reach $258.3 billion by 2028, growing at a compound annual growth rate (CAGR) of 7.9% from 2023 to 2028.
3. Market Drivers:

1. Rising research activities and funding investments for generic medicines are driving the market growth.
2. Technological advancements in contract development and manufacturing organizations (CDMOs) are also contributing to the growth.
3. The high cost of in-house drug development and the regulatory filling support provided by CDMOs are additional factors favoring the market.
4. Market Segmentation:
5. The market is segmented based on product, phase, application, and geography.
6. Regional Analysis:
7. The market is expected to grow across various regions, including Europe, Asia-Pacific, and Rest of the World (ROW).
8. Key Stakeholders:
9. The report includes comprehensive company profiles of major players in the market, such as 3M Co., AbbVie, Albany Molecular Research Inc. (AMRI), Baxter International Inc., Boehringer Ingelheim, Dr Reddy’s Laboratories Ltd., Lonza Group, Jubilant Life Sciences Ltd., Pfizer CentreOne, and Takeda Pharmaceuticals.
10. Research Study:
11. The study includes an industry trend analysis of the market, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behavior in the market.

These points provide a comprehensive overview of the global pharmaceutical contract development market, highlighting its growth prospects, key drivers, and major players.

Request Free Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=201524381

Pharmaceutical manufacturing services accounted for the largest share of the service segment in the pharmaceutical contract development and manufacturing market in 2022.

Based on service, the pharmaceutical contract development and manufacturing market is broadly segmented into pharmaceutical manufacturing services, drug development services, and biologic manufacturing services. In 2022, pharmaceutical manufacturing services accounted for the largest share of the pharmaceutical contract development and manufacturing market for service. This segment’s large share can be attributed to factors such as growing investments in developing novel therapies & pharma research. Further, growth in the pharma outsourcing trend is supported by the increased demand for lower-cost alternatives, which is likely to support the market growth.

The pharmaceutical API manufacturing services accounted for the largest share of the type segment in the pharmaceutical contract development and manufacturing market in 2022.

Based on type, the pharmaceutical manufacturing services is categorized into two sub-segments—pharmaceutical API manufacturing services and pharmaceutical FDF manufacturing services. In 2022, pharmaceutical API manufacturing services accounted for the largest share of the pharmaceutical manufacturing services segment. Factors such as the demand for API manufacturing are growing due to the looming patent expiries in several countries. Furthermore, pharma companies have shown a growing focus on conducting core activities that have pushed them to outsource API manufacturing.

Request 10% Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=201524381

Asia Pacific is likely to grow at the highest growth rate during the forecast period.

Based on the region The global pharmaceutical contract development and manufacturing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional segment. The Asia Pacific region is estimated to grow at the highest CAGR in the pharmaceutical contract development and manufacturing market during the forecast period. The growth of the pharmaceuticals and biopharmaceuticals market in the region is primarily driven by the rising prevalence of chronic disease conditions, the presence of a large number of CDMOs in the region, and significant investments in pharmaceutical R&D.

Recent Developments:

• In September 2022, Lonza Group collaborated with Touchlight, a biotechnology company. Lonza expanded its end-to-end offering for mRNA manufacturing with an additional source of DNA.
• In February 2022, Thermo Fisher Scientific collaborated with Moderna, Inc. for the large-scale manufacturing of Moderna’s COVID-19 vaccine, Spikevax, and other investigational mRNA medicines in its pipeline.
• In January 2023, Catalent supported the manufacturing of Sarepta’s most advanced gene therapy candidate, delandistrogene moxeparvovec (SRP-9001), to treat Duchenne muscular dystrophy.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.